The allocation of resources in the care for patients with panic disorder in Germany: an excess cost analysis informing policy and science.

Absenteeism Agoraphobia Costs Economic burden Panic disorder

Journal

Cost effectiveness and resource allocation : C/E
ISSN: 1478-7547
Titre abrégé: Cost Eff Resour Alloc
Pays: England
ID NLM: 101170476

Informations de publication

Date de publication:
2019
Historique:
received: 23 08 2018
accepted: 15 04 2019
entrez: 8 5 2019
pubmed: 8 5 2019
medline: 8 5 2019
Statut: epublish

Résumé

Panic disorder is a mental disorder of high prevalence, which frequently co-occurs with agoraphobia. There is a lack of studies measuring excess costs of panic disorder patients with and without agoraphobia. We compared costs of panic disorder patients with or without agoraphobia with costs of the anxiety-free population in Germany. Primary data from a cluster-randomized trial of adults suffering from panic disorder (n = 419) and from a representative survey of the German general population (N = 5005) were collected between 2012 and 2014. Missing data from the cluster-randomized trial were first imputed by multiple imputation using chained equations and subsequently balanced with the data from the survey by Entropy Balancing. The societal perspective was chosen. Excess costs were calculated by generalized linear models and two-part-models. Entropy Balancing led to an exact match between the groups. We found 6-month total excess costs of 3220€ (95% CI 1917€-4522€) for panic disorder patients without agoraphobia and of 3943€ (95% CI 2950€-4936€) for patient with agoraphobia. Panic disorder patients with or without agoraphobia had significantly higher costs for psychotherapy, general practitioners, general hospital stays and informal care Indirect costs accounted for approximately 60% of the total excess costs. Panic disorder with or without agoraphobia is associated with significant excess costs. Agoraphobia changes the pattern of resource utilization. Especially indirect costs are relevant. Agoraphobia influences resource utilization in the inpatient sector.

Sections du résumé

BACKGROUND BACKGROUND
Panic disorder is a mental disorder of high prevalence, which frequently co-occurs with agoraphobia. There is a lack of studies measuring excess costs of panic disorder patients with and without agoraphobia. We compared costs of panic disorder patients with or without agoraphobia with costs of the anxiety-free population in Germany.
METHODS METHODS
Primary data from a cluster-randomized trial of adults suffering from panic disorder (n = 419) and from a representative survey of the German general population (N = 5005) were collected between 2012 and 2014. Missing data from the cluster-randomized trial were first imputed by multiple imputation using chained equations and subsequently balanced with the data from the survey by Entropy Balancing. The societal perspective was chosen. Excess costs were calculated by generalized linear models and two-part-models.
RESULTS RESULTS
Entropy Balancing led to an exact match between the groups. We found 6-month total excess costs of 3220€ (95% CI 1917€-4522€) for panic disorder patients without agoraphobia and of 3943€ (95% CI 2950€-4936€) for patient with agoraphobia. Panic disorder patients with or without agoraphobia had significantly higher costs for psychotherapy, general practitioners, general hospital stays and informal care Indirect costs accounted for approximately 60% of the total excess costs.
CONCLUSIONS CONCLUSIONS
Panic disorder with or without agoraphobia is associated with significant excess costs. Agoraphobia changes the pattern of resource utilization. Especially indirect costs are relevant. Agoraphobia influences resource utilization in the inpatient sector.

Identifiants

pubmed: 31061640
doi: 10.1186/s12962-019-0177-4
pii: 177
pmc: PMC6487058
doi:

Types de publication

Journal Article

Langues

eng

Pagination

9

Investigateurs

Wolfgang Blank (W)
Florian Bleibler (F)
Jörg Breitbart (J)
Christian Brettschneider (C)
Antje Freytag (A)
Jochen Gensichen (J)
Thomas S Hiller (TS)
Heike Hoyer (H)
Bert Huenges (B)
Hans-Helmut König (HH)
Armin Mainz (A)
Jürgen Margraf (J)
Sylvia Sänger (S)
Mercedes Schelle (M)
Konrad Schmidt (K)
Nico Schneider (N)
Elisabeth Schöne (E)
Ulrike Schumacher (U)
Michael Sommer (M)
Tobias Teismann (T)
Paul Thiel (P)
Michel Wensing (M)

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
J Psychosom Res. 2003 Dec;55(6):515-9
pubmed: 14642981
Int J Technol Assess Health Care. 2005 Spring;21(2):165-71
pubmed: 15921055
Eur Neuropsychopharmacol. 2005 Aug;15(4):435-43
pubmed: 15925492
Br J Psychiatry. 2007 Apr;190:326-32
pubmed: 17401039
J Affect Disord. 2007 Dec;104(1-3):127-36
pubmed: 17466380
Prev Sci. 2007 Sep;8(3):206-13
pubmed: 17549635
Milbank Q. 2007 Dec;85(4):641-90
pubmed: 18070333
J Affect Disord. 2009 Apr;114(1-3):14-31
pubmed: 18768222
Z Psychosom Med Psychother. 2008;54(4):409-18
pubmed: 19049690
J Affect Disord. 2010 Apr;122(1-2):86-95
pubmed: 19616305
Depress Anxiety. 2010 Feb;27(2):113-33
pubmed: 20143426
Depress Anxiety. 2010 Apr;27(4):404-11
pubmed: 20143435
J Anxiety Disord. 2010 Aug;24(6):559-64
pubmed: 20418054
J Psychiatr Res. 2011 Feb;45(2):262-8
pubmed: 20609450
Health Econ. 2011 Aug;20(8):897-916
pubmed: 20799344
Int J Methods Psychiatr Res. 2011 Mar;20(1):40-9
pubmed: 21499542
Aust N Z J Psychiatry. 2011 Nov;45(11):957-67
pubmed: 22044173
Depress Anxiety. 2012 Sep;29(9):797-806
pubmed: 22585578
J Health Econ. 2013 May;32(3):546-58
pubmed: 23524035
Depress Anxiety. 2013 Oct;30(10):947-54
pubmed: 24108489
J Anxiety Disord. 2014 Jan;28(1):83-7
pubmed: 24440989
Trials. 2014 Apr 06;15:112
pubmed: 24708672
Int J Methods Psychiatr Res. 2014 Sep;23(3):304-19
pubmed: 24729411
Gesundheitswesen. 2015 Jan;77(1):53-61
pubmed: 25025287
Int Nurs Rev. 2015 Sep;62(3):340-50
pubmed: 26058542
J Affect Disord. 2016 Jan 15;190:75-83
pubmed: 26480214
EBioMedicine. 2015 Sep 08;2(10):1405-19
pubmed: 26629535
Health Policy. 2016 Feb;120(2):159-69
pubmed: 26797256
Trials. 2017 Aug 16;18(1):382
pubmed: 28814317
Am J Public Health Nations Health. 1967 Nov;57(11):1954-66
pubmed: 6069745

Auteurs

Christian Brettschneider (C)

1Department of Health Economics and Health Services Research, Hamburg Center for Health Economics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.

Florian Bleibler (F)

1Department of Health Economics and Health Services Research, Hamburg Center for Health Economics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.

Thomas S Hiller (TS)

2Institute of General Practice & Family Medicine, Jena University Hospital, Friedrich-Schiller-University, Bachstrasse 18, 07743 Jena, Germany.

Alexander Konnopka (A)

1Department of Health Economics and Health Services Research, Hamburg Center for Health Economics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.

Jörg Breitbart (J)

2Institute of General Practice & Family Medicine, Jena University Hospital, Friedrich-Schiller-University, Bachstrasse 18, 07743 Jena, Germany.

Jürgen Margraf (J)

3Mental Health Research and Treatment Center, Ruhr-University Bochum, Massenbergstrasse 9-13, 44787 Bochum, Germany.

Jochen Gensichen (J)

2Institute of General Practice & Family Medicine, Jena University Hospital, Friedrich-Schiller-University, Bachstrasse 18, 07743 Jena, Germany.
4Institute of General Practice and Family Medicine, University Hospital of Ludwig-Maximilians-University Munich, Pettenkoferstraße 10, 80336 Munich, Germany.

Hans-Helmut König (HH)

1Department of Health Economics and Health Services Research, Hamburg Center for Health Economics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.

Classifications MeSH